P18 is a tumor suppressor gene involved in human medullary thyroid carcinoma and pheochromocytoma development
暂无分享,去创建一个
R. Medema | E. Kalkhoven | R. Berger | C. Lips | M. Gloerich | D. Acton | W. van Veelen | R. Klompmaker | C. J. V. van Gasteren | J. Höppener
[1] D. Franklin,et al. Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development. , 2008, Cancer research.
[2] D. Franklin,et al. Simultaneous downregulation of CDK inhibitors p18Ink4c and p27Kip1 is required for MEN2A-RET-mediated mitogenesis , 2007, Oncogene.
[3] P. Pandolfi,et al. p18Ink4c and Pten Constrain a Positive Regulatory Loop between Cell Growth and Cell Cycle Control , 2006, Molecular and Cellular Biology.
[4] J. Cordier,et al. Idiopathic chronic eosinophilic pneumonia , 2006, Orphanet journal of rare diseases.
[5] F. Zindy,et al. The CDK Inhibitor p18Ink4c is a Tumor Suppressor in Medulloblastoma , 2006, Cell cycle.
[6] M. Hatten,et al. The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. , 2005, Genes & development.
[7] H. Yoshiji,et al. Reduced expression of cell cycle regulator p18INK4C in human hepatocellular carcinoma , 2004, Hepatology.
[8] Juan F. García,et al. Silencing of the p18INK4c gene by promoter hypermethylation in Reed-Sternberg cells in Hodgkin lymphomas. , 2004, Blood.
[9] A. Vettori,et al. Fine analysis of the short arm of chromosome 1 in sporadic and familial pheochromocytoma , 2003, Clinical endocrinology.
[10] D. Marsh,et al. Genome-wide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.
[11] V. Godfrey,et al. Haploinsufficiency of p18INK4c Sensitizes Mice to Carcinogen-Induced Tumorigenesis , 2003, Molecular and Cellular Biology.
[12] Ronen Marmorstein,et al. Structure-based Design of p18INK4cProteins with Increased Thermodynamic Stability and Cell Cycle Inhibitory Activity* , 2002, The Journal of Biological Chemistry.
[13] C. Larsson,et al. Loss of Heterozygosity on the Short Arm of Chromosome 1 in Pheochromocytoma and Abdominal Paraganglioma , 2002, World Journal of Surgery.
[14] V. P. Collins,et al. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. , 2001, The American journal of pathology.
[15] B. Boehm,et al. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. , 2001, The Journal of clinical endocrinology and metabolism.
[16] K. Hoang-Xuan,et al. P18 tumor suppressor gene and progression of oligodendrogliomas to anaplasia , 2000, Neurology.
[17] V. Godfrey,et al. Functional Collaboration between Different Cyclin-Dependent Kinase Inhibitors Suppresses Tumor Growth with Distinct Tissue Specificity , 2000, Molecular and Cellular Biology.
[18] M. Tsai,et al. Tumor suppressor INK4: quantitative structure-function analyses of p18INK4C as an inhibitor of cyclin-dependent kinase 4. , 2000, Biochemistry.
[19] N. Skakkebaek,et al. Cell cycle regulators in testicular cancer: Loss of p18INK4C marks progression from carcinoma in situ to invasive germ cell tumours , 2000, International journal of cancer.
[20] M. Wolter,et al. Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors. , 1999, Journal of neuropathology and experimental neurology.
[21] W. Yarbrough,et al. Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors. , 1999, Journal of the National Cancer Institute.
[22] M. Tsai,et al. Tumor suppressor INK4: determination of the solution structure of p18INK4C and demonstration of the functional significance of loops in p18INK4C and p16INK4A. , 1999, Biochemistry.
[23] Y. Xiong,et al. Identification of functional elements of p18INK4C essential for binding and inhibition of cyclin-dependent kinase (CDK) 4 and CDK6. , 1999, Cancer research.
[24] G. Peters,et al. The p16INK4a/CDKN2A tumor suppressor and its relatives. , 1998, Biochimica et biophysica acta.
[25] A. Blais,et al. Structure of the gene encoding the human cyclin-dependent kinase inhibitor p18 and mutational analysis in breast cancer. , 1998, Biochemical and biophysical research communications.
[26] K. Spirin,et al. Analysis of p18INK4C in adult T‐cell leukaemia and non‐Hodgkin's lymphoma , 1997, British journal of haematology.
[27] H. Koeffler,et al. Molecular analysis of the INK4 family of genes in prostate carcinomas. , 1997, The Journal of urology.
[28] R. Maestro,et al. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression , 1997, International journal of cancer.
[29] J. Lapointe,et al. A p18 mutant defective in CDK6 binding in human breast cancer cells. , 1996, Cancer research.
[30] G. Peters,et al. Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma , 1996, Molecular and cellular biology.
[31] T. Goodrow,et al. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. , 1996, Cancer research.
[32] P. Pollock,et al. Compilation of somatic mutations of the CDKN2 gene in human cancers: Non‐random distribution of base substitutions , 1996, Genes, chromosomes & cancer.
[33] C. Bartram,et al. Molecular analysis of the cyclin‐dependent kinase inhibitor family: p16(CDKN2/MTS1/INK4A), p18(INK4C) and p27(Kip1) genes in neuroblastomas , 1996, Cancer.
[34] H. Koeffler,et al. Alterations of the p15, p16,and p18 genes in osteosarcoma. , 1996, Cancer genetics and cytogenetics.
[35] Carl W. Miller,et al. Molecular analysis of a family of cyclin‐dependent kinase inhibitor genes (p15/MTS2/INK4b and p18/INK4c) in non‐small cell lung cancers , 1995, Molecular carcinogenesis.
[36] B. Ponder,et al. Genotype‐phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium , 1995, Journal of internal medicine.
[37] C. Bartram,et al. Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. , 1995, Blood.
[38] James M. Roberts,et al. Inhibitors of mammalian G1 cyclin-dependent kinases. , 1995, Genes & development.
[39] P. Goodfellow,et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[40] C. Healey,et al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. , 1994, Human molecular genetics.
[41] R. Hofstra,et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma , 1994, Nature.
[42] P. Goodfellow,et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. , 1993, Human molecular genetics.
[43] B. Ponder,et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A , 1993, Nature.
[44] C. Mathew,et al. Genetic events in tumour initiation and progression in multiple endocrine neoplasia type 2 , 1993, Genes, chromosomes & cancer.
[45] D. Schaid,et al. Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas. , 1991, The Journal of clinical investigation.
[46] Samaan Na,et al. Deletion mapping on the distal third region of chromosome 1p in multiple endocrine neoplasia type IIA. , 1990 .
[47] C. Mathew,et al. Deletion of genes on chromosome 1 in endocrine neoplasia , 1987, Nature.
[48] P. Pandolfi,et al. p18 Ink4c and Pten constrain a positive regulatory loop between cell growth and cell cycle control. , 2006, Molecular and cellular biology.
[49] V. Godfrey,et al. CDK inhibitors p18 INK4c and p27 Kip1 mediate two separate pathways to collaboratively suppress pituitary tumorigenesis , 1998 .
[50] R. Marmorstein,et al. Crystal structure of the CDK4/6 inhibitory protein p18INK4c provides insights into ankyrin-like repeat structure/function and tumor-derived p16INK4 mutations , 1998, Nature Structural Biology.
[51] L. Mulligan,et al. Mutations of the RET proto‐oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease , 1997, Human mutation.
[52] C. Nguyen,et al. Deletion mapping on the distal third region of chromosome 1p in multiple endocrine neoplasia type IIA. , 1990, Anticancer research.